3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight

Key Points

• Investors are increasingly looking beyond mega-cap tech stocks toward small-caps with improving fundamentals and unique growth catalysts amid wide valuation gaps.
• Ascentage Pharma and Maze Therapeutics are biotech companies with promising oncology and kidney disease drug pipelines, strong cash positions, and Buy ratings from analysts.
• Pagaya Technologies has shown strong revenue and net income growth through AI-driven credit decisions, earning a bullish consensus price target from Wall Street analysts.

Small-cap companies are accustomed to living in the shadow of mega-cap tech firms, but there are signs that the market backdrop could be changing for some of these companies. Investors have been looking beyond the Magnificent Seven for growth opportunities, and smaller companies with improving fundamentals, unique business models, or other noteworthy catalysts may finally have an opportunity to win investor attention.

As interest rates have recently risen, it may be a chance for contrarian investors to buy in before economic conditions continue to improve for small companies seeking financing. At the same time, the distinction between valuations of large- and small-caps remains atypically wide, which means that there may be chances to rotate into smaller names if the risk environment improves. Of course, small-caps still come with their share of risks, including volatility, operational concerns, cash flow, and more. But with all this in mind, the three companies below may stand out for their fundamentals and unique catalysts that could indicate growth going forward.

An Oncology Biotech Poised for a Commercial Breakthrough

Ascentage Pharma Group International NASDAQ: AAPG is moving from a clinical-stage biotech company into a more established commercial oncology business thanks to its primary commercial product, olverembatinib, used to treat certain types of leukemia. The company has also expanded its pipeline and has hematology and oncology candidates in various ongoing clinical trials.

For the first half of 2026, revenue climbed by more than 29% year over year (YOY) to $44.5 million, fueled by $41.6 million in product sales. The company's reach is global, and its business has been particularly strong in China. At the same time, it maintained more than $279 million in cash and equivalents as of the midpoint of the year, providing a runway through the end of 2027.

Ascentage carries many of the typical risks and opportunities associated with growth-stage biotech firms. It is still unprofitable and spends cash quickly, as R&D costs increased by nearly a third YOY in H1 2026, and the company anticipates significant capital needs to facilitate commercialization going forward. Its success also hinges on key trial results and approvals for its pipeline.

Nonetheless, the fact that commercial revenue is scaling and the company has strong drug prospects going forward has earned it a unanimous Buy rating from 10 analysts, along with a price target of $46.43.

Multiple Promising Drug Candidates and Strong Financials for Maze

Another biotech company with upcoming clinical milestones that could drive growth, Maze Therapeutics NASDAQ: MAZE, focuses on genetically driven diseases. Its primary drug candidate is MZE829, which targets APOL1-mediated kidney disease (AMKD), a condition affecting more than 1 million people in the United States alone. Maze reported positive topline data for a Phase 2 trial of MZE829 in March 2026, a critical step toward approval and eventual commercialization.

The company stands out for having additional drug candidate opportunities. Additional Phase 2 studies for other drugs in development are expected in the coming quarters. While the results of these pending trials are unclear, the fact that the company has a more diversified pipeline than some of its competitors helps it stand out.

Maze also distinguishes itself by its financial position: the company had about $528 million in cash and equivalents as of its most recent earnings report, thanks to a successful capital raise. This should provide it sufficient runway to extend operations into 2029 while limiting near-term financing risks. The combination of more stable financials and promising drugs in development has led analysts to overwhelmingly rate MAZE shares a Buy. As with AAPG above, Wall Street expects MAZE shares to more than double.

Pagaya's Volumes and Profitability Could Win Over Skeptics

Fintech firm Pagaya Technologies Ltd. NASDAQ: PGY has successfully integrated AI and data analytics to help lenders make credit decisions. The company enjoyed strong revenue growth of about 19% YOY for the latest quarter, combined with GAAP net income that surged by more than 180% over the same period.

The company is performing well on multiple fronts: partners have sent more volume, revenues from fees less production costs are soaring, and expenses have remained stable. With it earning up to about 5% in net fees per loan issued, Pagaya can afford to be asset-light to aid in its profitability. On top of that, an increase in volume has helped to put to rest the lingering concern that Pagaya may not have enough investors willing to take on loans.

To be sure, Pagaya remains a riskier play than some other fintech names owing to its size, the risks to the funding market overall, the potential for a macro slowdown, and more. However, Wall Street analysts are heavily bullish on PGY shares and have assigned a fairly lofty consensus price target of $31.25 per share.